Distinguished Prof Annemarie Hennessy AM celebrates 20 years at HRI
Distinguished Professor Annemarie Hennessy AM is celebrating 20 years at HRI as Vascular Immunology Group Leader this year.
HRI welcomes new Scientific Director, Prof Andrew Coats AO
HRI is delighted to announce that world-leading cardiovascular expert Professor Andrew Coats AO is joining the Institute as Scientific Director.
Advancing medical treatment for diabetes patients more likely to develop atherosclerosis
HRI's Dr Ashish Misra has received a 2022 Diabetes Australia research grant for his project to identify the mechanisms linking diabetes with atherosclerosis.
Extending the CHAANZ Congenital Heart Disease Registry to NZ
HRI is establishing the Congenital Heart Alliance of Australia and New Zealand (CHAANZ) Congenital Heart Disease Registry, a comprehensive NZ registry of demographic and clinical data from cohorts of paediatric and adult cases of CHD from sites across New Zealand.
New therapeutic strategies for stiff heart failure
HRI has launched an international research project investigating new therapeutic strategies for stiff heart failure.
Dr Yen Chin Koay wins ISHR International Poster Prize
Dr Yen Chin Koay of HRI’s Cardiometabolic Disease Group was awarded the International Poster Prize at the XXIV World Congress International Society for Heart Research (ISHR) 2022, Berlin, Germany.
The Congenital Heart Fitness Intervention Trial bringing hope
HRI is embarking on “CH-FIT: The Congenital Heart Fitness Intervention Trial” to investigate the benefits of exercise for people with congenital heart disease.
Sepsis research accelerated by James N. Kirby Foundation Grant
Dr Christopher Stanley’s research focuses on cardiovascular decline seen in sepsis, also known as septic shock – for which there is no clinical treatment.
Is myeloperoxidase the key to preventing heart attack and stroke?
Dr James Nadel has published a literature review in Cardiovascular Research which explores the role of myeloperoxidase (MPO) in cardiovascular disease.